AIHTA - Publications - Search - Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020

Götz, G. and Hawlik, K. (2020): Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020. Decision Support Document 106/ Update 2020.

[thumbnail of DSD_106_Update2020.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Extracorporeal cytokine adsorption therapy (ECAT) aims to reduce the cytokine concentration in the blood, thereby stabilising the overall immune response in sepsis and SIRS (Systemic Inflammatory Response Syndrome). We investigated the efficacy and safety of ECAT in its two main indications: to treat sepsis and to prevent SIRS (Systemic Inflammatory Response Syndrome) during cardiopulmonary bypass surgery.

This update systematic review captures evidence consisting of seven randomised controlled trials: Five randomised controlled trials with a total of 197 enrolled patients (of whom 163 were analysed) investigated the preventive use of the technology in patients undergoing cardiac surgery. Further two randomised controlled trials with 120 enrolled patients (of whom 117 were analysed) investigated the therapeutic use of the technology in patients with sepsis or septic shock. Overall, the certainty of the evidence was very low mainly due to high imprecision and the high risk of bias in most of the included studies.

Current evidence is insufficient to show a clinical benefit of ECAT used as an add-on measure preventively in cardiac surgery or therapeutically in patients with sepsis or septic shock. Based on the selected patient-relevant crucial outcomes, none of the studies was able to demonstrate that ECAT and standard care is more effective than -and as safe- as standard care alone in these two assessed conditions.

Item Type:Decision Support Document
Keywords:Sepsis, septic shock, SIRS, extracorporeal therapy, cytokines, cardiopulmonary bypass
Subjects:W Health professions > W 100-275 Medical, dental and pharmaceutical service plans
WB Practice of medicine > WB 300-962 Therapeutics
WD Disorders of systemic, metabolic or environmental origin > WD 300-375 Immunologic and collagen diseases
WH Hemic and lymphatic systems
WX Hospitals and other health facilities > WX 218 Intensive care units. Critical care (General)
Series Name:Decision Support Document 106/ Update 2020
Deposited on:15 Jul 2020 10:40
Last Modified:15 Jul 2020 18:02

Repository Staff Only: item control page